Heart failure and stepdown units of the Sydell and Arnold Miller Family Heart & Vascular Institute have been testing electrocardiogram technology.
Quantitative Pericardial DHE: A Helpful Clinical Tool in Recurrent Pericarditis?
A new study finds quantitative delayed hyperenhancement on cardiac MR imaging offers insight into disease duration and expected response to treatment in patients with recurrent pericarditis.
Speckle-Tracking Echo for Assessment of Myocardial Strain: A Case in Images
A brief case vignette showcases the clinical setting in which this increasingly popular strain-based heart imaging technique may have its greatest diagnostic and prognostic value.
What’s in Store for Cardiac Surgery at Cleveland Clinic and Beyond?
In this Q&A, Cleveland Clinic’s new Cardiothoracic Surgery Chair shares his vision for the department he now leads, the future of his specialty and collaboration in cardiovascular care.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A Twofer for Cleveland Clinic in 2017 ASE Lifetime Achievement Awards
Both of this year’s lifetime honors in echocardiography went to Cleveland Clinic caregivers — Dr. William Stewart won the physician award and Margaret (Koko) Park earned the sonographer prize.
Sex-Specific Differences in CRT Response: Have We Cracked the Code?
New studies on male-female differences in response to cardiac resynchronization therapy promise to reshape the way patients are selected to receive CRT devices. The lead investigator explains how.
Vascular Surgery and Medicine by the Numbers at Cleveland Clinic (Infographic)
When a center has an annual vascular surgery case volume beyond 7,500 and one of the largest vascular medicine programs in the U.S., it’s bound to yield some notable stats. Here’s a sampling.
SYNTAX Substudy: CABG’s Edge Over PCI Extends to Long-Term QoL
The trial’s new health status analysis gives even more reason to consider CABG the preferred revascularization strategy for patients with anatomically complex three-vessel or left main disease.
Valve-in-Valve TAVR’s Safety Is Validated in Major Registry Study
The lead investigator of the STS/ACC TVT Registry study presented at ACC.17 explains why its findings suggest valve-in-valve TAVR might be the treatment of choice for inoperable and even high-risk patients.
Dr. Nissen Recaps PCSK9 News from ACC (Video)
FOURIER was the big news out of ACC, but other PCSK9 inhibitor trials mattered as well, including its EBBINGHAUS substudy and the SPIRE and ORION-1 trials. Dr. Steven Nissen outlines the takeaways.